BlackRock's iShares Bitcoin Trust recorded a $665.2 million net inflow on Monday, the largest single-day inflow since October 2025, driving US spot Bitcoin ETFs to a total of about $527 million in net inflows. This surge contrasts with outflows from Fidelity and Grayscale Bitcoin funds, which lost $83.6 million and $54.9 million respectively. Meanwhile, spot Ether ETFs continued their outflow streak with $103.3 million withdrawn. The inflows occurred as Bitcoin traded in a narrow range near $82,000-$83,000, reflecting resilient institutional demand despite macroeconomic uncertainties. BlackRock also filed for a new Bitcoin fund offering downside protection, signaling ongoing innovation in crypto investment products.
BlackRock's Bitcoin ETF inflow is the story context, and for readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 20, 2026 15:21 WIB: Among 50 major cryptocurrencies priced on Pluang, 18 rose and 31 fell today. Notable movers include SXP (Solar) down 46.27% to Rp37 with a typical hold time of 94 days, BAL (Balancer) up 11.14% to Rp16.297 with a typical hold time of 85 days, and BAT (Basic Attention Token) up 9.71% to Rp3.587 with a nearly balanced buy/sell order activity and a typical hold time of 93 days. The largest one-day price change was SXP's 46.27% drop.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
AL Sydbank A/S executed transactions to buy back 30,000 shares during week 45 as part of its ongoing share buyback program announced in February 2026, which totals DKK 1.1 billion. The program started in March 2026 and will conclude by January 2027, ...
AL Sydbank A/S continued its share buyback program in week 45, purchasing 30,000 shares at an average price of around 725 DKK, totaling approximately 21.76 million DKK. The buyback program, announced in February 2026 and running until January 2027, a...
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
